Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer
Critical priority
The issue
Product safety
Affected product
Xeljanz and Xeljanz XR (tofacitinib), a prescription drug used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.